SNDL Inc. (SNDL), the Calgary-based Canadian cannabis and liquor retailer formerly known as Sundial Growers, is one of the more speculative names in the cannabis sector. With shares trading near $1.29, the question of whether the stock can climb toward a $3.25 stock price target implies a very large move — roughly 150% — and rests on whether management can turn around its struggling Cannabis Operations segment while capitalizing on its U.S. investments.
Coverage of SNDL is limited, which makes any average analyst price target less statistically robust than for a large-cap stock. Two current, attributable targets were identified. Alliance Global Partners analyst Aaron Grey maintains a Buy rating with a $3.50 target, trimmed from $5.00 in July 2026 after third-quarter results. ATB Cormark Capital Markets analyst Frederico Gomes maintains a Buy rating with a $3.00 target, lowered from $3.50 on October 29, 2026.
The average of these two targets is $3.25, with a range of $3.00 to $3.50. Both analysts acknowledge near-term pressure — including costs tied to the Jeeter ramp and softer liquor and cannabis retail demand — while pointing to SNDL's completed restructuring of Parallel and expected improvement in sales and cash flow as reasons to stay constructive. Because only two analysts cover the stock, this $3.25 figure should be read as a rough midpoint of opinion rather than a broad market consensus.
SNDL shares have traded near $1.29 in early November 2026, within a 52-week range of roughly $1.13 to $2.34. Reaching the $3.25 central target would require a gain of about 150%, which is a very large move. Even the lower end of the range, $3.00, implies more than a doubling from current levels.
The path would depend on a fundamental re-rating of the business. SNDL's third-quarter 2026 results showed progress in some areas — record free cash flow of roughly C$20 million and a return to positive adjusted operating income — but also a 2.5% year-over-year decline in net revenue and a C$52 million non-cash goodwill impairment tied to Cannabis Operations. Closing the valuation gap implied by the analyst targets would likely require sustained free cash flow, a recovery in Cannabis Operations, and greater visibility on U.S. consolidation.
Several verifiable factors could support a higher valuation. SNDL repurchased about 23 million shares year-to-date — roughly 9% of shares outstanding at the start of 2026 — and has proposed a substantial issuer bid of up to C$50 million at a price not exceeding US$1.35 per share. The company also holds a debt-free balance sheet and delivered record gross margins in both Liquor and Cannabis Retail.
The U.S. expansion is a key theme. SNDL increased its indirect equity ownership in Parallel to approximately 92%, giving it exposure to 56 retail locations and three cultivation and manufacturing sites across Florida, Texas, and Massachusetts. Management is evaluating paths to consolidate the medical cannabis business, and an expected EU-GMP certification at its Atholville facility could open international sales and reduce processing costs.
The principal obstacle is Cannabis Operations, where net revenue fell 27.7% year-over-year and gross margin turned negative at -6% following the exit from the domestic dried-flower category. SNDL has initiated a strategic review of the segment, including potential divestitures, but the outcome is uncertain.
Broader headwinds also persist. Liquor Retail same-store sales declined 6% amid softer market demand, and cannabis retail same-store sales fell 3.8% as Alberta and Ontario markets contracted. Separately, the expected deconsolidation of Ontario franchise operations would reduce reported net revenue by about C$105 million, though with only a modest impact on operating income. These factors, combined with thin analyst coverage, create meaningful uncertainty around the average analyst price target.
On a technical basis, the stock's 52-week high near $2.34 stands as a meaningful resistance level that the shares would need to reclaim before the analyst targets become relevant. The $1.13 low provides nearby support, with the $1.00 and $2.00 marks acting as psychological levels. A move toward $3.25 would represent a breakout well beyond the stock's recent trading range, underscoring the magnitude of the required re-rating.
Analyst price targets typically reflect a research horizon of about 12 months, though the two firms covering SNDL have not published a uniform timeframe. Key items to watch include fourth-quarter 2026 results and any benefits from cost reductions at the Kelowna facility, the outcome of the strategic review of Cannabis Operations, progress on consolidating Parallel, the EU-GMP certification, and resolution of the regulatory matters with the Alcohol and Gaming Commission of Ontario. Analyst revisions and any change in the substantial issuer bid also matter for sentiment.
For traders who prefer a data-driven approach, AI Daily Buy/Sell Signals from Tickeron uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening allows. Those interested in a systematic view of SNDL and the broader market can explore the AI Daily Buy/Sell Signals to complement their own research.
The $3.25 central target is the arithmetic mean of two Buy-rated analyst targets, $3.00 and $3.50, and implies a roughly 150% move from SNDL's recent price near $1.29. The supportive case rests on buybacks, record free cash flow, and the potential value of the Parallel U.S. platform, while the bearish case centers on persistent losses in Cannabis Operations, declining revenue, and very thin coverage. Reaching $3.25 would require a fundamental transformation in profitability and a decisive market re-rating, not simply incremental improvement. No guarantee can be made that the stock will reach this level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SNDL has been closely correlated with CGC. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if SNDL jumps, then CGC could also see price increases.
| Ticker / NAME | Correlation To SNDL | 1D Price Change % | ||
|---|---|---|---|---|
| SNDL | 100% | N/A | ||
| CGC - SNDL | 77% Closely correlated | -2.67% | ||
| TLRY - SNDL | 76% Closely correlated | +0.43% | ||
| CRON - SNDL | 73% Closely correlated | -2.45% | ||
| OGI - SNDL | 68% Closely correlated | -2.27% | ||
| ACB - SNDL | 65% Loosely correlated | -1.95% | ||
More | ||||